id,gene_symbol,protein_name,tier,evidence_priority,has_structure,surface_class,pdb_count_total,alphafold_mean_pLDDT,has_cryoEM,has_activation_state_pdb_pair,activation_state_pdb_active,activation_state_pdb_inactive,has_known_aptamer,aptamer_count_pubmed,aptamer_pmids,in_cev_map,opentargets_top_disease_name,opentargets_top_disease_score
P51795,CLCN5,H(+)/Cl(-) exchange transporter 5,Tier 1.5,0.955,1,A_surface,2,80.62,0,0,,,0,0,,1,Dent disease type 1,0.850724240157394
O00571,DDX3X,ATP-dependent RNA helicase DDX3X,Tier 1,0.951,1,A_surface,17,72.19,0,0,,,0,0,,1,X-linked non-syndromic intellectual disability,0.8362533125067105
P25189,MPZ,Myelin protein P0,Tier 1.5,0.951,1,A_surface,2,81.69,0,0,,,0,0,,1,Charcot-Marie-Tooth disease type 1B,0.8377022197539885
P54760,EPHB4,Ephrin type-B receptor 4,Tier 1,0.95,1,A_surface,23,82.0,0,0,,,0,0,,1,Capillary malformation - arteriovenous malformation,0.8317426466005666
Q8WZA1,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",Tier 1,0.948,1,A_surface,10,89.88,0,0,,,0,0,,1,"muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3",0.826104223872448
P13473,LAMP2,Lysosome-associated membrane glycoprotein 2,Tier 1.5,0.948,1,A_surface,2,83.19,0,0,,,0,0,,1,Glycogen Storage Disease Type 2b,0.8273010649608126
O94766,B3GAT3,Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3,Tier 1,0.94,1,A_surface,3,92.56,0,0,,,0,0,,1,"Larsen-like syndrome, B3GAT3 type",0.7995331164339264
Q14118,DAG1,Dystroglycan 1,Tier 1,0.938,1,A_surface,8,68.19,0,0,,,0,0,,1,autosomal recessive limb-girdle muscular dystrophy type 2P,0.7935290060634741
Q9UPN3,MACF1,"Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5",Tier 1,0.938,1,A_surface,3,,0,0,,,0,0,,1,lissencephaly 9 with complex brainstem malformation,0.7945569032416216
P08473,MME,Neprilysin,Tier 1,0.937,1,A_surface,16,96.19,0,0,,,0,0,,1,Charcot-Marie-Tooth disease axonal type 2T,0.7912653398252156
P35916,FLT4,Vascular endothelial growth factor receptor 3,Tier 1,0.937,1,A_surface,2,72.44,0,0,,,0,0,,1,lymphatic malformation 1,0.7904355931811005
O75880,SCO1,Cytochrome c oxidase assembly factor SCO1,Tier 1,0.935,1,A_surface,10,77.75,0,0,,,0,0,,1,"mitochondrial complex IV deficiency, nuclear type 4",0.7827872588103603
O94856,NFASC,Neurofascin,Tier 1.5,0.933,1,A_surface,2,76.31,0,0,,,0,0,,1,neurodevelopmental disorder with central and peripheral motor dysfunction,0.7782432580663833
Q15746,MYLK,"Myosin light chain kinase, smooth muscle",Tier 1.5,0.93,1,A_surface,7,65.88,0,0,,,0,0,,1,"aortic aneurysm, familial thoracic 7",0.7659842793171938
O95714,HERC2,E3 ubiquitin-protein ligase HERC2,Tier 1,0.925,1,A_surface,15,,0,0,,,0,0,,1,developmental delay with autism spectrum disorder and gait instability,0.74952129063985
Q02413,DSG1,Desmoglein-1,Tier 1.5,0.92,1,A_surface,1,62.06,0,0,,,0,0,,1,severe dermatitis-multiple allergies-metabolic wasting syndrome,0.7335328506238418
Q9Y6N7,ROBO1,Roundabout homolog 1,Tier 1,0.897,1,A_surface,12,60.0,0,0,,,0,0,,1,neurooculorenal syndrome,0.6567040910170603
Q13555,CAMK2G,Calcium/calmodulin-dependent protein kinase type II subunit gamma,Tier 1.5,0.891,1,A_surface,2,78.38,0,0,,,0,0,,1,intellectual developmental disorder 59,0.6354497016986491
P31431,SDC4,Syndecan-4,Tier 1,0.885,1,A_surface,5,63.28,0,0,,,0,0,,1,non-small cell lung carcinoma,0.6168120240815278
Q92956,TNFRSF14,Tumor necrosis factor receptor superfamily member 14,Tier 1.5,0.879,1,A_surface,8,79.94,0,0,,,0,0,,1,diffuse large B-cell lymphoma,0.5983171413833771
P20701,ITGAL,Integrin alpha-L,Tier 1,0.877,1,A_surface,41,82.62,0,0,,,0,0,,1,psoriasis,0.5899795223699872
P0DOY3,IGLC3,Immunoglobulin lambda constant 3,Tier 1,0.876,1,A_surface,4,96.06,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P01859,IGHG2,Immunoglobulin heavy constant gamma 2,Tier 1,0.876,1,A_surface,5,87.38,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P01857,IGHG1,Immunoglobulin heavy constant gamma 1,Tier 1,0.876,1,A_surface,100,86.69,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P01597,IGKV1-39,Immunoglobulin kappa variable 1-39,Tier 1.5,0.876,1,A_surface,2,90.5,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P01764,IGHV3-23,Immunoglobulin heavy variable 3-23,Tier 1.5,0.876,1,A_surface,6,91.0,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P23083,IGHV1-2,Immunoglobulin heavy variable 1-2,Tier 1.5,0.876,1,A_surface,1,91.75,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P01593,IGKV1D-33,Immunoglobulin kappa variable 1D-33,Tier 1.5,0.876,1,A_surface,6,90.88,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P06312,IGKV4-1,Immunoglobulin kappa variable 4-1,Tier 1.5,0.876,1,A_surface,10,90.62,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
Q10588,BST1,ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2,Tier 1,0.869,1,A_surface,6,89.62,0,0,,,0,0,,1,Parkinson disease,0.5634966060310903
Q16513,PKN2,Serine/threonine-protein kinase N2,Tier 1,0.868,1,A_surface,4,71.44,0,0,,,0,0,,1,neurodegenerative disease,0.5587297348479079
P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,Tier 1,0.866,1,A_surface,9,76.94,0,0,,,0,0,,1,ulcerative colitis,0.5526669305497712
Q96D96,HVCN1,Voltage-gated hydrogen channel 1,Tier 1.5,0.865,1,A_surface,2,69.75,0,0,,,0,0,,1,Joubert syndrome,0.5504227269701596
Q12913,PTPRJ,Receptor-type tyrosine-protein phosphatase eta,Tier 1,0.864,1,A_surface,5,77.75,0,0,,,0,0,,1,neurodegenerative disease,0.54699134609967
Q9P1W8,SIRPG,Signal-regulatory protein gamma,Tier 1.5,0.864,1,A_surface,2,85.5,0,0,,,0,0,,1,type 1 diabetes mellitus,0.5457344827318543
O15155,BET1,BET1 homolog,Tier 1.5,0.864,1,A_surface,1,83.06,0,0,,,0,0,,1,neurodegenerative disease,0.5468418315282804
P04439,HLA-A,"HLA class I histocompatibility antigen, A alpha chain",Tier 1,0.863,1,A_surface,100,87.12,0,0,,,0,0,,1,diffuse large B-cell lymphoma,0.5431777522591615
P35052,GPC1,Glypican-1,Tier 1,0.863,1,A_surface,4,82.5,0,0,,,0,0,,1,COVID-19,0.5430103345490354
P29320,EPHA3,Ephrin type-A receptor 3,Tier 1,0.863,1,A_surface,28,80.75,0,0,,,0,0,,1,medullary thyroid gland carcinoma,0.5426301743186921
P34741,SDC2,Syndecan-2,Tier 1.5,0.863,1,A_surface,1,60.84,0,0,,,0,0,,1,COVID-19,0.5422254875204983
Q15811,ITSN1,Intersectin-1,Tier 1,0.859,1,A_surface,11,72.31,0,0,,,0,0,,1,genetic disorder,0.5312614627352166
O00161,SNAP23,Synaptosomal-associated protein 23,Tier 1.5,0.859,1,A_surface,2,82.12,0,0,,,0,0,,1,neurodegenerative disease,0.5288361677964304
P54756,EPHA5,Ephrin type-A receptor 5,Tier 1.5,0.858,1,A_surface,2,79.38,0,0,,,0,0,,1,neurodegenerative disease,0.5261379875719714
P54762,EPHB1,Ephrin type-B receptor 1,Tier 1,0.856,1,A_surface,8,83.62,0,0,,,0,0,,1,medullary thyroid gland carcinoma,0.5204553830376101
Q9HCM2,PLXNA4,Plexin-A4,Tier 1.5,0.856,1,A_surface,1,83.06,0,0,,,0,0,,1,neurodegenerative disease,0.518371001420808
P15814,IGLL1,Immunoglobulin lambda-like polypeptide 1,Tier 1.5,0.85,1,A_surface,3,75.06,0,0,,,0,0,,1,isolated agammaglobulinemia,0.4996673834185043
P78552,IL13RA1,Interleukin-13 receptor subunit alpha-1,Tier 1,0.846,1,A_surface,4,81.56,0,0,,,0,0,,1,type 2 diabetes mellitus,0.48627783096767857
P18084,ITGB5,Integrin beta-5,Tier 1.5,0.846,1,A_surface,3,82.19,0,0,,,0,0,,1,migraine disorder,0.48652455084344876
P19440,GGT1,Glutathione hydrolase 1 proenzyme,Tier 1,0.845,1,A_surface,12,94.81,0,0,,,0,0,,1,alcoholic liver disease,0.48228227774828414
P01889,HLA-B,"HLA class I histocompatibility antigen, B alpha chain",Tier 1,0.845,1,A_surface,100,88.06,0,0,,,0,0,,1,COVID-19,0.48417012135481613